Skip to main content
. 2012 Oct 1;4(6):1117–1123. doi: 10.3892/etm.2012.733

Figure 1.

Figure 1

Schematic presentation of the experimental treatment protocol. White field, Krebs solution; black field, no-flow ischemia. DL-propargylglycine (PAG), an inhibitor H2S of synthesis, was administered 20 min prior to ischemic treatment. CON, control; IPO, ischemic postconditioning; I, ischemia; R, reperfusion; C, cycles.